- Call Us: +91 8985 000 888
- Email: bank@tran-scell.com
Hematopoietic stem cell transplantation replaces damaged bone marrow, treating conditions like leukemia and lymphoma
Personalizing Hematopoietic Stem Cell Transplantation (HSCT) through advanced cell technology mediums represents a transformative approach in enhancing treatment efficacy and patient outcomes. By utilizing innovative bioreactors and 3D cell culture systems, researchers can optimize the expansion and differentiation of stem cells tailored to individual patient profiles. This personalized methodology allows for better matching of donor and recipient characteristics, minimizing complications like graft-versus-host disease. Furthermore, integrating genomic and proteomic analyses can refine the selection of stem cell sources, ensuring that each transplant is not only more effective but also more aligned with the patient's unique biological makeup. As a result, personalized HSCT has the potential to revolutionize the treatment landscape for hematological malignancies and other blood disorders
Due to a restructuring within the Transcell group, cell technology For HSCT has been added to Biolife's portfolio from Oncologics
The medically accepted standard for best cryostorage is under an environment of vaporized Liquid Nitrogen (LN2) which is maintained at -196 degree C. The process of cryostorage can only be undertaken by specialized facilities which not only have the physical components for cryostorage but also qualified and experienced resources for clinically processing therapy grade cells
Bone marrow, peripheral blood and cord blood are all sources of hematopoietic cells while these sources differ regarding collection methods, cellular content. CD34+ sub population, T-cell depleted cell population and NK cells are therapy grade useful in personalizing transplantation procedure
Graft-versus-host disease (GVHD) is an inflammatory disease that happens in Allogeneic transplantation. In GvHD, the donated bone marrow or peripheral blood stem cells view the recipient’s body as foreign, and the donated cells/bone marrow attack the body. This can occur even if the donor and recipient are HLA-identical because the immune system can still recognize other differences between their tissues. It is aptly named graft-versus-host disease because bone-marrow transplantation is the only transplant procedure in which the transplanted cells must accept the body rather than the body accepting the new cells
Specially primed immune cells that can kill certain cells, including foreign cells, cancer cells, and cells infected with a virus. Cytotoxic T lymphocytes can be separated from donor blood cells, grown in the laboratory, and then given to patients to kill cancer cells. BKV-specific, CMV and EBV-specific CTLs are safe and effective interventions in managing post HSCT complications